For the quarter ending 2025-09-30, SABS made -$47,498,825 in revenue. $45,445,469 in net income. Net profit margin of -95.68%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 8,970,010 | 6,996,660 | 7,473,640.667 | 7,830,745 |
| General and administrative | 3,708,959 | 2,735,401 | 3,500,880.667 | 3,478,621 |
| Total operating expenses | 12,678,969 | 9,732,061 | 10,974,521.333 | 11,309,366 |
| Total revenue | - | - | 330,602.5 | - |
| Loss from operations | -12,678,969 | -9,732,061 | -10,533,718 | -11,309,366 |
| Changes in fair value of warrant liabilities | -61,598,908 | 627,056 | -1,792,946 | -6,171 |
| Interest expense | 43,292 | 64,345 | 80,121.667 | 78,036 |
| Interest income | 655,233 | 13,562 | 336,274.667 | 277,174 |
| Other income | 765,881 | 295,630 | 565,986 | 754,647 |
| Warrant issuance cost | 4,852,292 | - | - | - |
| Total other income | 58,124,438 | -382,209 | 2,615,085 | 959,956 |
| Income (loss) from continuing operations before income taxes, noncontrolling interest | - | - | - | -10,349,410 |
| Net income (loss) | 45,445,469 | -10,114,270 | -7,918,633 | -10,349,410 |
| Earnings per share, diluted, total | -0.21 | -1.09 | -0.853 | -1.12 |
| Net loss per share, basic | 0.5 | -1.09 | -0.853 | -1.12 |
| Weighted-average common shares outstanding - basic | 10,660,500 | 9,294,469 | 908.667 | 9,259,192 |
| Weighted-average common shares outstanding - diluted | 77,863,263 | 9,294,469 | 908.667 | 9,259,192 |
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)